Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sun Pharma to acquire Novartis’ Odomzo

Sun Pharma to acquire Novartis’ Odomzo

3rd January 2017

Sun Pharma is to acquire the oncology drug Odomzo from Novartis for an upfront fee of 175 million dollars (142 million pounds), subject to anti-trust clearance and further closing conditions. Additional undisclosed fees described as 'milestone payments' will also be incurred.
 
The drug represents Sun Pharma's first branded oncology product and currently has marketing approval in more than 30 countries, including the US and Australia.
 
It is used to treat adult patients with locally advanced basal cell carcinoma (BCC) after it has returned following surgery or radiation therapy.
 
BCC is a form of non-melanoma skin cancer, representing around 75 percent of cases of the disease. It is most often diagnosed in the elderly or middle-aged patients.
 
Commenting on the acquisition, Sun Pharma's global head of business development Kirti Ganorkar said: "We see meaningful global potential for Odomzo by leveraging Sun Pharma's existing dermatology and oncology infrastructure to provide an innovative product to BCC patients worldwide."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801830665-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.